Scleroderma (Systemic Sclerosis) – Epidemiology – Emerging Markets
Clarivate Epidemiology's coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide. We report both the incidence and prevalence of scleroderma (systemic sclerosis) for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology's scleroderma (systemic sclerosis) forecast will answer the following questions:
- In developing countries, what impact will economic growth and development have on the number of people living with a diagnosis of scleroderma (systemic sclerosis)?
- Of all people diagnosed with scleroderma (systemic sclerosis), how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of scleroderma (systemic sclerosis) over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts eleven scleroderma (systemic sclerosis) patient populations, as follows:
- Diagnosed incident cases.
- Diagnosed prevalent cases.
- Diagnosed prevalent cases of diffuse cutaneous SSc.
- Diagnosed prevalent cases of limited cutaneous SSc.
- Diagnosed prevalent cases of limited or unspecified SSc.
- Diagnosed prevalent cases with comorbid ILD.
- Diagnosed prevalent cases with no comorbid ILD.
- Diagnosed prevalent cases with comorbid PAH.
- Diagnosed prevalent cases with no comorbid PAH.
- Drug-treated prevalent cases.
- Non-drug-treated prevalent cases.
Note: coverage may vary by country.
Table of contents
- Scleroderma (Systemic Sclerosis) - Epidemiology - Emerging Markets
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of systemic sclerosis)
- Diagnosed prevalent cases
- Diagnosed incidence
- Disease subtypes by severity
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviation Table
Deepika Chauhan, M.P.H., Epidemiologist, Epidemiology. Her focus is on oncology indications such as non-small-cell lung cancer, colorectal cancer, and gastric cancer. Prior to this role, she was an intern with DRG Analytics, where she worked with cross-functional teams to deliver analytical solutions to clients. Ms. Chauhan also worked at Drexel University as a research assistant on the EPA’s project to prevent Legionnaire’s disease in residential buildings. She graduated with an M.P.H. degree in epidemiology from Drexel University and holds a bachelor’s degree in medicine.
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.